Classification of anticancer drugs: an update with FDA- and EMA-approved drugs.
Level 5 - mechanism / opinion, no new human data
Narrative review proposing a conceptual classification framework without new empirical data.
PubMed 38965194 · doi:10.1007/s10555-024-10188-5
What was done
The authors proposed a revised classification framework for FDA- and EMA-approved anticancer systemic therapies to accommodate newer agents that do not fit conventional categories. The system organizes drugs across two levels: the anatomical or physiological site of action (tumor cell, tumor vasculature, immune system, or endocrine system) and the molecular mechanism of action.
What was found
The abstract reports no empirical data or quantitative metrics. It describes the structural outline of the proposed two-level classification system.
Why it matters
As oncology therapeutics diversify beyond traditional cytotoxic and targeted categories, updated classification frameworks can help clinicians, researchers, and educators systematically organize novel anticancer mechanisms.
Limits
The abstract describes a conceptual taxonomic framework with no empirical testing, validation methodology, or quantitative analysis reported. It does not provide clinical efficacy, safety, or comparative drug data.
Cited by
- supports There are over 100 different types of chemotherapy drugs and dozens of approved immunotherapies for cancer.